Indeed, teriflunomide treatment in patients with relapsing-remitting MS (RRMS) resulted in downregulation of B cell CD80 and CD86 expression, reducing pathogenicity (Wu et al., 2023). Here, CD86 is linked to relapsing-remitting multiple sclerosis.